tetano
Editor, Senior Moderator
J Infect Chemother
. 2021 Dec 30;S1341-321X(21)00351-2.
doi: 10.1016/j.jiac.2021.12.015. Online ahead of print.
Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan
Shinya Otsuka[SUP] 1 [/SUP], Kei Hiraoka[SUP] 2 [/SUP], Masato Suzuoki[SUP] 3 [/SUP], Hideki Ujiie[SUP] 4 [/SUP], Tatsuya Kato[SUP] 5 [/SUP], Isao Yokota[SUP] 6 [/SUP], Kazuya Yonezawa[SUP] 7 [/SUP], Keiji Oguma[SUP] 8 [/SUP], Nozomu Iwashiro[SUP] 9 [/SUP], Mototsugu Kato[SUP] 10 [/SUP], Masanori Ohara[SUP] 11 [/SUP]
Affiliations
Abstract
Introduction: The effectiveness of several vaccines against coronavirus disease (COVID-19) has been reported in the real-world setting. However, it is still unknown how long antibodies persist following vaccination and whether or not the persistence of antibodies has a protective effect against COVID-19.
Methods: Healthcare workers who had received two doses of the BNT162b2 mRNA COVID-19 vaccine were enrolled, and a single-center study was conducted at the National Hospital Organization Hakodate National Hospital. Serum samples from all participants were collected 13-21 weeks (median: 20 weeks) after the second dose of vaccination. The antibody titers were measured using an electrochemiluminescence immunoassay (Elecsys® Anti-SARS-CoV-2 S). Data on characteristics of the participants were gathered from patient records and interview sheets.
Results: A total of 401 participants, among whom 70.1% were women and the median age was 42 years, were evaluated in this study. None of the participants had a definite COVID-19 history, and all participants who received complete vaccination showed positive antibody titers. The antibody titer was observed to be higher in participants with younger age (p < 0.001) and those who were females (p = 0.028). Despite the higher risk of infection than that of the general public, no vaccinated staff developed breakthrough infections.
Conclusions: This study demonstrates the significant contribution of the BNT162b2 vaccine in the acquisition of anti-SARS-CoV-2S antibodies; therefore, the general population should benefit from these two vaccine doses, which are expected to be protective for at least five months.
Keywords: Antibody; COVID-19; SARS-CoV-2; Vaccination.
. 2021 Dec 30;S1341-321X(21)00351-2.
doi: 10.1016/j.jiac.2021.12.015. Online ahead of print.
Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan
Shinya Otsuka[SUP] 1 [/SUP], Kei Hiraoka[SUP] 2 [/SUP], Masato Suzuoki[SUP] 3 [/SUP], Hideki Ujiie[SUP] 4 [/SUP], Tatsuya Kato[SUP] 5 [/SUP], Isao Yokota[SUP] 6 [/SUP], Kazuya Yonezawa[SUP] 7 [/SUP], Keiji Oguma[SUP] 8 [/SUP], Nozomu Iwashiro[SUP] 9 [/SUP], Mototsugu Kato[SUP] 10 [/SUP], Masanori Ohara[SUP] 11 [/SUP]
Affiliations
- PMID: 35016824
- PMCID: PMC8716179
- DOI: 10.1016/j.jiac.2021.12.015
Abstract
Introduction: The effectiveness of several vaccines against coronavirus disease (COVID-19) has been reported in the real-world setting. However, it is still unknown how long antibodies persist following vaccination and whether or not the persistence of antibodies has a protective effect against COVID-19.
Methods: Healthcare workers who had received two doses of the BNT162b2 mRNA COVID-19 vaccine were enrolled, and a single-center study was conducted at the National Hospital Organization Hakodate National Hospital. Serum samples from all participants were collected 13-21 weeks (median: 20 weeks) after the second dose of vaccination. The antibody titers were measured using an electrochemiluminescence immunoassay (Elecsys® Anti-SARS-CoV-2 S). Data on characteristics of the participants were gathered from patient records and interview sheets.
Results: A total of 401 participants, among whom 70.1% were women and the median age was 42 years, were evaluated in this study. None of the participants had a definite COVID-19 history, and all participants who received complete vaccination showed positive antibody titers. The antibody titer was observed to be higher in participants with younger age (p < 0.001) and those who were females (p = 0.028). Despite the higher risk of infection than that of the general public, no vaccinated staff developed breakthrough infections.
Conclusions: This study demonstrates the significant contribution of the BNT162b2 vaccine in the acquisition of anti-SARS-CoV-2S antibodies; therefore, the general population should benefit from these two vaccine doses, which are expected to be protective for at least five months.
Keywords: Antibody; COVID-19; SARS-CoV-2; Vaccination.